MEPOLIZUMAB
mepolizumab 100 mg/mL injection, 1 mL pen device
MEPOLIZUMAB (15515N)
15515N
Manner of administration:Injection
Restriction
Indication: Uncontrolled chronic obstructive pulmonary disease (COPD)
Treatment phase: Initial treatment (New patients; or Recommencement of treatment in a new treatment
cycle following a break in PBS-subsidised biological medicine therapy)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 6 | DPMQ: $1,605.34 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Nucala | |||||